ARISTOTLE
2011
Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF
In 18,201 patients with AF and ≥ 1 stroke risk factor, apixaban reduced stroke or systemic embolism, major bleeding and all-cause mortality compared with warfarin.
Result
Primary endpoint: Stroke or systemic embolism
1.27 %/yr vs 1.60 %/yr. Major bleed 2.13 % vs 3.09 %.
- Subtopic
- Anticoagulation
- Design
- Double-blind, double-dummy RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ESC 2024 AFACC/AHA 2023 AF
- Source
- Granger CB, et al. N Engl J Med. 2011;365(11):981-992.doi 10.1056/NEJMoa1107039
Discussion & critique
Apixaban is the only NOAC superior on all three: stroke, bleed, mortality. Dose-reduction criteria (age ≥ 80, weight ≤ 60 kg, Cr ≥ 1.5) are often misapplied in practice.